No regulatory body has ever evaluated the cumulative ingredient load of the US childhood vaccine schedule as a whole. Each vaccine is approved individually. The schedule as a system — including the timing, combinations, and cumulative adjuvant burden — has never been studied in a controlled trial. This chart maps what package inserts disclose, dose by dose, from pregnancy through age 18.
The FDA's maximum daily parenteral aluminum threshold for premature infants (established for IV nutrition) is 5 mcg/kg/day. A full-term newborn weighing 3.5 kg has an FDA threshold of 17.5 mcg/day. The 2-month visit on the standard ACIP schedule delivers 680–1,225 mcg of aluminum in a single clinical encounter — 39 to 70 times that daily threshold.
Ingredient Categories — Color Key
Aluminum adjuvant
— injected; bypasses gut; depot effect
Mercury / Thimerosal
— ethylmercury preservative; multi-dose vials
Human Fetal Cell Lines
— WI-38, MRC-5, HEK-293
Formaldehyde
— used in manufacturing; residual present
Polysorbate 80 / Other
— surfactant; blood-brain barrier permeability
The Schedule — Dose by Dose
All ingredient data sourced from FDA-approved package inserts. Aluminum values in micrograms (mcg). Where brand options differ, both are listed.
Prenatal
Maternal vaccines — administered during pregnancy
Note: No vaccine is FDA-approved for use during pregnancy. These are ACIP recommendations only.
Tdap — Boostrix (GSK)
Aluminum: 390 mcg (aluminum hydroxide) |
Mercury: 0 |
Formaldehyde: ≤100 mcg (glutaraldehyde ≤50 ng) |
Polysorbate 80: ≤100 mcg
Al 390 mcg
Formaldehyde
Polysorbate 80
Source: FDA-approved package insert — Boostrix
Tdap — Adacel (Sanofi)
Aluminum: 1,500 mcg (aluminum phosphate) |
Mercury: 0 |
Formaldehyde: 5 mcg
Al 1,500 mcg
Formaldehyde
Source: FDA-approved package insert — Adacel
Influenza — Multi-Dose Vial (various manufacturers)
Aluminum: 0 |
Mercury: 25 mcg thimerosal per dose |
Formaldehyde: ≤100 mcg |
Egg protein present
Hg 25 mcg
Formaldehyde
Source: FDA-approved package inserts — Fluzone, Fluvirin (multi-dose)
Influenza — Single-Dose Vial ("thimerosal-free")
Aluminum: 0 |
Mercury: trace <1 mcg — NOT mercury-zero. Trace thimerosal remains from manufacturing process even in "thimerosal-free" labeled vials |
Formaldehyde: ≤100 mcg
Hg trace <1 mcg
Formaldehyde
Source: FDA-approved package inserts — Fluzone single-dose
COVID mRNA — Comirnaty (Pfizer) / Spikevax (Moderna)
Aluminum: 0 |
Mercury: 0 |
Comirnaty: PEG (polyethylene glycol) in lipid nanoparticles |
Spikevax: polysorbate 80 |
HEK-293 human embryonic kidney cells used in development and confirmatory testing
HEK-293 (development)
PEG / Polysorbate 80
Source: FDA-approved package inserts — Comirnaty, Spikevax
RhoGAM — Anti-D Immunoglobulin (Rh-Negative Mothers Only)
Given to all Rh-negative mothers at 28 weeks and again at delivery — including when the baby is also Rh-negative. The fetal blood type is not tested before the 28-week injection; it is given as a precaution.
Multi-dose vials (HyperRHO S/D): Mercury 25 mcg thimerosal per dose | Single-dose vials (Rhophylac, WinRho SDF): Mercury trace <1 mcg — not mercury-zero | Contains polysorbate 80.
Multi-dose vials (HyperRHO S/D): Mercury 25 mcg thimerosal per dose | Single-dose vials (Rhophylac, WinRho SDF): Mercury trace <1 mcg — not mercury-zero | Contains polysorbate 80.
Hg 0–25 mcg (vial-type dependent)
Polysorbate 80
Geier & Geier (2007–2008): 28.3% of ASD children had Rh-negative mothers vs. 14.4% of controls; signal normalized after thimerosal removal in 2001. Three subsequent larger studies — Miles & Takahashi 2007 (n=214 families), Croen et al. 2008 (population-based, Kaiser Permanente), Price et al. 2010 (Pediatrics, 256 ASD vs. 752 controls) — found no association. Current peer-reviewed weight: signal not replicated; causal link not established. The formal investigation this pattern warranted has not been conducted. Thimerosal formulation remains in multi-dose vials still in clinical use.
Source: FDA-approved package inserts — HyperRHO S/D, Rhophylac, WinRho SDF | Geier DA & Geier MR. J Matern Fetal Neonatal Med. 2007;20(5):385–390.
Prenatal aluminum — brand dependent
Boostrix
390 mcg
or
Adacel
1,500 mcg
Plus influenza mercury (25 mcg/dose MDV) if multi-dose vial used. Injected before birth.
Birth
Day 0–3 · Hospital administration
Hepatitis B — Dose 1
Recombivax HB pediatric (Merck): Aluminum: 250 mcg (amorphous aluminum hydroxyphosphate sulfate, AAHS) | Mercury: 0 | Formaldehyde: 0 | Yeast-derived antigen. No fetal cells.
Engerix-B pediatric (GSK): Aluminum: 250 mcg (aluminum hydroxide) | Mercury: 0. No fetal cells.
Al 250 mcg
Source: FDA-approved package inserts — Recombivax HB, Engerix-B
Cumulative aluminum — after birth
250 mcg
Injected into a newborn who may weigh as little as 2.5 kg
1–2 Months
Hepatitis B dose 2
Hepatitis B — Dose 2
Aluminum: 250 mcg (same formulation as dose 1) | Mercury: 0. No fetal cells.
Al 250 mcg
Source: FDA-approved package inserts — Recombivax HB, Engerix-B
Cumulative aluminum — after dose 2
500 mcg
Two Hepatitis B doses; child is now 1–2 months old
2 Months
Major multi-vaccine visit — highest single-day aluminum exposure
High-load visit
DTaP — Daptacel (Sanofi)
Aluminum: 330 mcg (aluminum phosphate) |
Formaldehyde: 5 mcg |
Polysorbate 80: ≤0.1 mg | No fetal cells.
Al 330 mcg
Formaldehyde
Polysorbate 80
Source: FDA-approved package insert — Daptacel
DTaP — Infanrix (GSK) — alternate brand
Aluminum: 625 mcg (aluminum hydroxide) |
Formaldehyde: ≤100 mcg |
Polysorbate 80: ≤100 mcg | No fetal cells.
Al 625 mcg
Formaldehyde
Polysorbate 80
Source: FDA-approved package insert — Infanrix
Hib — PedvaxHIB (Merck)
Aluminum: 225 mcg (aluminum hydroxyphosphate sulfate) | No fetal cells.
Al 225 mcg
ActHIB (Sanofi): Aluminum: 0 | No fetal cells. No adjuvant.
Source: FDA-approved package inserts — PedvaxHIB, ActHIB
PCV13 — Prevnar 13 (Pfizer)
Aluminum: 125 mcg (aluminum phosphate) | No fetal cells.
Al 125 mcg
Source: FDA-approved package insert — Prevnar 13
IPV — IPOL (Sanofi)
Aluminum: 0 |
Formaldehyde: residual from inactivation process |
Polysorbate 80: residual |
Streptomycin, neomycin, polymyxin B: trace antibiotics |
Vero cells (monkey kidney — not human fetal).
Formaldehyde residual
Polysorbate 80
Source: FDA-approved package insert — IPOL
Rotavirus — RotaTeq / Rotarix (oral)
Aluminum: 0 | Mercury: 0 |
Oral administration only — not injected. No adjuvants.
Source: FDA-approved package inserts — RotaTeq, Rotarix
FDA Aluminum Safety Threshold — Comparison
The FDA's maximum daily parenteral aluminum for premature infants is 5 mcg/kg/day. A full-term newborn at 3.5 kg has a daily FDA threshold of 17.5 mcg.
2-month visit (Daptacel path)
680 mcg
= 39x the FDA daily threshold
2-month visit (Infanrix path)
975 mcg
= 56x the FDA daily threshold
If Hep B also given same day (Infanrix path)
1,225 mcg
= 70x the FDA daily threshold
The FDA threshold was established for IV nutrition in premature infants — not as a safety clearance for vaccine adjuvants. The FDA has not stated that it applies to vaccine aluminum. This comparison uses the only published federal parenteral aluminum reference point that exists.
Visit aluminum — 2-month
Daptacel + PedvaxHIB + PCV13
680 mcg
Infanrix + PedvaxHIB + PCV13
975 mcg
Cumulative aluminum — after 2-month visit (with prior Hep B doses)
~930 – 1,475 mcg
Range reflects brand choice. Child is 8 weeks old.
4 Months
Repeat of 2-month schedule — dose 2 series
DTaP dose 2, Hib dose 2, PCV dose 2, IPV dose 2, Rotavirus dose 2
Same formulations and ingredient loads as the 2-month visit. Hepatitis B is not routinely given at this visit.
Visit aluminum — 4-month
680 – 975 mcg
Cumulative aluminum — after 4-month visit
~1,610 – 2,450 mcg
Child is 4 months old. Cumulative load now exceeds 1,600 mcg minimum.
6 Months
Dose 3 series + Hepatitis B dose 3 + first influenza
DTaP dose 3, Hib dose 3, PCV dose 3
Same formulations as prior visits. Aluminum load: 680–975 mcg for this visit (DTaP + Hib/PedvaxHIB + PCV13).
Al 680–975 mcg this visit
Hepatitis B — Dose 3
Aluminum: 250 mcg | Mercury: 0. Same formulation as prior doses.
Al 250 mcg
Source: FDA-approved package inserts — Recombivax HB, Engerix-B
Influenza — Dose 1 (first year, first dose)
Multi-dose vial (common in clinical settings): Mercury 25 mcg thimerosal | Formaldehyde ≤100 mcg |
Single-dose: mercury trace <1 mcg | Aluminum: 0 in either formulation.
Hg 0–25 mcg
Formaldehyde
Source: FDA-approved package inserts — Fluzone multi-dose, single-dose
COVID mRNA — First Doses (6 Months+)
Both mRNA COVID vaccines are authorized for infants beginning at 6 months. These are primary series doses — not boosters.
Comirnaty (Pfizer-BioNTech) — 6 months to 4 years: Aluminum 0 | Mercury 0 |
PEG in lipid nanoparticles | 3-dose primary series (doses at 0, 3–8 weeks, and 8+ weeks) |
HEK-293 human embryonic kidney cells used in development and confirmatory testing.
Spikevax (Moderna) — 6 months to 5 years: Aluminum 0 | Mercury 0 |
PEG in lipid nanoparticles | 2-dose primary series (doses 4 weeks apart) |
HEK-293 cells used in confirmatory testing.
HEK-293 (development/testing)
PEG (lipid nanoparticles)
Source: FDA-approved package inserts — Comirnaty (6 mo–4 yr formulation), Spikevax (6 mo–5 yr formulation)
Cumulative aluminum — after 6-month visit
~2,315 – 3,675 mcg
Plus 0–25 mcg mercury from influenza, depending on vial type. Child is 6 months old.
12–15 Months
Human fetal cell-line vaccines introduced — MMR, Varicella, Hepatitis A
Hib — Dose 4
PedvaxHIB: Aluminum 225 mcg | ActHIB: Aluminum 0
Al 0–225 mcg
PCV13 — Prevnar 13 — Dose 4
Aluminum: 125 mcg (aluminum phosphate). No fetal cells.
Al 125 mcg
MMR — M-M-R II (Merck)
Aluminum: 0 | Mercury: 0 | Gelatin (porcine) | Neomycin (trace)
Human Fetal Cell Line Disclosure
Rubella component (RA 27/3 strain): Propagated in WI-38 human diploid lung fibroblasts. WI-38 = female lung tissue from a 3-month fetus electively aborted in 1961, Wistar Institute, Philadelphia, PA.
Measles component: Chick embryo cell culture — not human fetal.
Mumps component (Jeryl Lynn strain): Chick embryo cell culture — not human fetal.
WI-38 (rubella component)
Source: FDA-approved package insert — M-M-R II; Plotkin SA, Am J Dis Child 1965
Varicella — Varivax (Merck)
Aluminum: 0 | Mercury: 0 | Gelatin (porcine) | Neomycin (trace)
Human Fetal Cell Line Disclosure
MRC-5 human diploid lung cells: Male lung tissue from a 14-week fetus electively aborted in 1966, Medical Research Council, United Kingdom. Disclosed on product package insert.
MRC-5
Source: FDA-approved package insert — Varivax
Hepatitis A — Dose 1
Havrix pediatric (GSK): Aluminum: 250 mcg (aluminum hydroxide) | Formaldehyde: ≤0.1 mg | Fetal cells: MRC-5
Vaqta pediatric (Merck): Aluminum: 250 mcg | Formaldehyde: non-detectable | Fetal cells: MRC-5
Al 250 mcg
MRC-5
Formaldehyde
Source: FDA-approved package inserts — Havrix, Vaqta
Visit aluminum — 12–15 month
350 – 600 mcg
Cumulative aluminum — after 12–15 month visit
~2,665 – 4,275 mcg
First exposure to human fetal cell-line vaccines. Three separate cell lines introduced: WI-38 (MMR rubella) and MRC-5 (Varicella, Hep A).
15–18 Months
DTaP dose 4
DTaP — Dose 4
Daptacel: Aluminum 330 mcg | Infanrix: Aluminum 625 mcg | Formaldehyde, polysorbate 80. No fetal cells.
Al 330–625 mcg
Formaldehyde
Polysorbate 80
Cumulative aluminum — after 15–18 month visit
~2,995 – 4,900 mcg
Child is 15–18 months old.
18–23 Months
Hepatitis A — dose 2
Hepatitis A — Dose 2
Aluminum: 250 mcg | Fetal cells: MRC-5 | Formaldehyde. Same formulation as dose 1.
Al 250 mcg
MRC-5
Formaldehyde
Source: FDA-approved package inserts — Havrix, Vaqta
Cumulative aluminum — after 18–23 month visit
~3,245 – 5,150 mcg
4–6 Years
Booster doses — DTaP, IPV, MMR, Varicella
DTaP — Dose 5 (final childhood dose)
Daptacel: Aluminum 330 mcg | Infanrix: Aluminum 625 mcg | Formaldehyde, polysorbate 80. No fetal cells.
Al 330–625 mcg
Formaldehyde
Polysorbate 80
IPV — Dose 4
Aluminum: 0 | Formaldehyde residual, polysorbate 80 residual, trace antibiotics. Vero cells.
Formaldehyde residual
Polysorbate 80
MMR — Dose 2
Aluminum: 0 | Fetal cells: WI-38 (rubella component). Same formulation as dose 1.
WI-38 (rubella)
Varicella — Dose 2
Aluminum: 0 | Fetal cells: MRC-5. Same formulation as dose 1.
MRC-5
Influenza (annual)
Mercury: 0–25 mcg depending on vial type. Formaldehyde ≤100 mcg. Aluminum: 0.
Hg 0–25 mcg
Formaldehyde
Cumulative aluminum — after 4–6 year visit
~3,575 – 5,775 mcg
Child enters school age carrying a cumulative injected aluminum load of up to 5,775 mcg.
11–12 Years
Adolescent visit — Tdap booster, HPV series, Meningococcal
Major aluminum addition
Tdap Booster
Boostrix: Aluminum 390 mcg | Adacel: Aluminum 1,500 mcg | Formaldehyde (both). No fetal cells.
Al 390–1,500 mcg
Formaldehyde
HPV — Gardasil 9 (Merck)
Aluminum: 500 mcg (AAHS — amorphous aluminum hydroxyphosphate sulfate) |
Polysorbate 80 present | Mercury: 0 | No fetal cells | Yeast-derived.
Al 500 mcg
Polysorbate 80
Source: FDA-approved package insert — Gardasil 9. Series: 2–3 doses. Each dose contains 500 mcg aluminum.
Meningococcal MCV4 — Menactra / Menveo
Aluminum: 0 (Menactra and Menveo are aluminum-free) | Mercury: 0. No fetal cells.
Source: FDA-approved package inserts — Menactra, Menveo
Visit aluminum — 11–12 year (single HPV dose + Tdap Boostrix)
890 mcg
With Adacel instead: up to 2,000 mcg in one visit. HPV series = 3 doses total = 1,500 mcg aluminum from HPV alone.
Cumulative aluminum — after 11–12 year visit
~4,465 – 7,775 mcg
Range reflects all brand variables from birth through adolescence. Full HPV series adds further 1,000 mcg (2nd and 3rd doses).
16 Years
Meningococcal booster + annual influenza
Meningococcal Booster (MCV4)
Aluminum: 0. Same formulation as 11–12 year dose.
Influenza (annual)
Mercury: 0–25 mcg depending on vial type. Formaldehyde ≤100 mcg. Aluminum: 0.
Hg 0–25 mcg
Formaldehyde
Annual
Every year, all ages from 6 months onward
Influenza Vaccine — Cumulative Mercury Exposure
Multi-dose vials contain 25 mcg mercury (thimerosal) per dose. Single-dose "thimerosal-free" vials retain trace mercury from manufacturing — labeled thimerosal-free but not mercury-zero. Neither formulation is mercury-zero.
Cumulative mercury — birth through age 18
Up to 450 mcg
If multi-dose vials used at every annual influenza visit from birth through age 18 (18 doses × 25 mcg)
Source: FDA-approved package inserts — Fluzone multi-dose, Fluvirin multi-dose
Schedule Summary
Total Aluminum by Age 12
~4,465 –
7,775 mcg
7,775 mcg
Before HPV series completion and before annual flu boosters. Full HPV series adds 1,500 mcg.
Maximum Cumulative Mercury
450 mcg
If multi-dose influenza vials used at every annual visit, birth through age 18. Single-dose vials are not mercury-zero.
Vaccines Using Human Fetal Cell Lines
5
MMR (rubella — WI-38), Varicella (MRC-5), Hepatitis A (MRC-5), Varicella booster (MRC-5), COVID confirmatory testing (HEK-293).
VICP Compensation Paid
$5.7 billion
Total paid by the Vaccine Injury Compensation Program as of 2024. Manufacturers bear no direct liability under the 1986 National Childhood Vaccine Injury Act.
Human Fetal Cell Lines — On the Record
The following cell lines are documented in primary scientific literature and on FDA-approved product package inserts. They are not disclosed in standard verbal informed consent before vaccine administration. Parents and patients have a legal right to request and read product package inserts before any injection.
WI-38
Origin: Female lung tissue from a 3-month fetus electively aborted in 1961, Wistar Institute, Philadelphia, PA.
Used in: MMR — rubella component (RA 27/3 strain). All doses of MMR through the childhood and adolescent schedule.
Documentation: Plotkin SA, et al. "Clinical trials of immunization with the RA 27/3 strain of rubella virus." Am J Dis Child, 1965. Disclosed on M-M-R II package insert, Section 11 (Description).
Used in: MMR — rubella component (RA 27/3 strain). All doses of MMR through the childhood and adolescent schedule.
Documentation: Plotkin SA, et al. "Clinical trials of immunization with the RA 27/3 strain of rubella virus." Am J Dis Child, 1965. Disclosed on M-M-R II package insert, Section 11 (Description).
MRC-5
Origin: Male lung tissue from a 14-week fetus electively aborted in 1966, Medical Research Council, United Kingdom.
Used in: Varicella (Varivax), Hepatitis A (Havrix, Vaqta), Zostavax (shingles, adults), Rabies (Imovax, RabAvert), MMRV (ProQuad).
Documentation: Disclosed on all product package inserts under Section 11 (Description) and/or Section 13 (Nonclinical Toxicology/Manufacturing). The cell line is referenced as "human diploid lung fibroblasts" or "MRC-5 cells" depending on the insert.
Used in: Varicella (Varivax), Hepatitis A (Havrix, Vaqta), Zostavax (shingles, adults), Rabies (Imovax, RabAvert), MMRV (ProQuad).
Documentation: Disclosed on all product package inserts under Section 11 (Description) and/or Section 13 (Nonclinical Toxicology/Manufacturing). The cell line is referenced as "human diploid lung fibroblasts" or "MRC-5 cells" depending on the insert.
HEK-293
Origin: Human embryonic kidney cells from a fetus aborted approximately 1973, Netherlands. Established by researcher Alex van der Eb at Leiden University.
Used in: Confirmatory testing during Janssen (Johnson & Johnson) COVID-19 vaccine development. Some COVID vaccine production lines. Used extensively as a research and production cell line across pharmaceutical development.
Documentation: van der Eb AJ, et al. "Transformation with specific fragments of adenovirus DNAs." Cold Spring Harb Symp Quant Biol, 1979. FDA briefing documents, Janssen COVID-19 EUA, 2021.
Used in: Confirmatory testing during Janssen (Johnson & Johnson) COVID-19 vaccine development. Some COVID vaccine production lines. Used extensively as a research and production cell line across pharmaceutical development.
Documentation: van der Eb AJ, et al. "Transformation with specific fragments of adenovirus DNAs." Cold Spring Harb Symp Quant Biol, 1979. FDA briefing documents, Janssen COVID-19 EUA, 2021.
These cell lines are not disclosed in standard verbal informed consent before administration. The information is available in product package inserts, which parents and patients have a legal right to request and read before any injection. Under 21 CFR 610.15 and the National Childhood Vaccine Injury Act, vaccine information statements (VIS sheets) do not substitute for the full package insert. You may request the package insert at any clinical encounter.
Data Source
All ingredient data on this page is sourced from FDA-approved product package inserts. Package inserts are the legal disclosure documents manufacturers are required to publish for every approved biological product. They are publicly available at dailymed.nlm.nih.gov and on each manufacturer's website. Aluminum figures are stated in the package insert under "Description" (Section 11) or "How Supplied/Storage and Handling." Where package inserts state a range, the insert-disclosed range is shown. The cumulative totals on this page use the dose ranges from individual inserts and reflect the ACIP-recommended schedule as published. The schedule as a whole — combinations, timing, cumulative load — has not been evaluated in a controlled safety trial.
Go deeper
The vaccine article covers the full picture
Package insert Section 13. VAERS adverse event data. The 1986 Act that removed manufacturer liability. The placebo trial problem. Historical mortality vs. vaccine timing. The Japan schedule comparison.
Knowledge up →